Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for multiple myeloma

More patients treated with isatuximab, bortezomib, lenalidomide, and dexamethasone had improved progression-free survival and had a complete or better response than those treated with VRd alone.

Saved in:

Bibliographic Details
Main Authors:	Facon, Thierry (Author) , Dimopoulos, Meletios-Athanasios (Author) , Leleu, Xavier P. (Author) , Beksac, Meral (Author) , Pour, Ludek (Author) , Hájek, Roman (Author) , Liu, Zhuogang (Author) , Minarik, Jiri (Author) , Moreau, Philippe (Author) , Romejko-Jarosinska, Joanna (Author) , Spicka, Ivan (Author) , Vorobyev, Vladimir I. (Author) , Besemer, Britta (Author) , Ishida, Tadao (Author) , Janowski, Wojciech (Author) , Kalayoglu-Besisik, Sevgi (Author) , Parmar, Gurdeep (Author) , Robak, Pawel (Author) , Zamagni, Elena (Author) , Goldschmidt, Hartmut (Author) , Martin, Thomas G. (Author) , Manier, Salomon (Author) , Mohty, Mohamad (Author) , Oprea, Corina (Author) , Brégeault, Marie-France (Author) , Macé, Sandrine (Author) , Berthou, Christelle (Author) , Bregman, David (Author) , Klippel, Zandra (Author) , Orlowski, Robert Z. (Author)
Format:	Article (Journal)
Language:	English
Published:	June 3, 2024
In:	The New England journal of medicine Year: 2024, Volume: 391, Issue: 17, Pages: 1597-1609
ISSN:	1533-4406
DOI:	10.1056/NEJMoa2400712
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1056/NEJMoa2400712 Verlag, lizenzpflichtig, Volltext: https://www.nejm.org/doi/full/10.1056/NEJMoa2400712
Author Notes:	Thierry Facon, Meletios-Athanasios Dimopoulos, Xavier P. Leleu, Meral Beksac, Ludek Pour, Roman Hájek, Zhuogang Liu, Jiri Minarik, Philippe Moreau, Joanna Romejko-Jarosinska, Ivan Spicka, Vladimir I. Vorobyev, Britta Besemer, Tadao Ishida, Wojciech Janowski, Sevgi Kalayoglu-Besisik, Gurdeep Parmar, Pawel Robak, Elena Zamagni, Hartmut Goldschmidt, Thomas G. Martin, Salomon Manier, Mohamad Mohty, Corina Oprea, Marie-France Brégeault, Sandrine Macé, Christelle Berthou, David Bregman, Zandra Klippel, and Robert Z. Orlowski, for the IMROZ Study Group

Description
Summary:	More patients treated with isatuximab, bortezomib, lenalidomide, and dexamethasone had improved progression-free survival and had a complete or better response than those treated with VRd alone.
Item Description:	Gesehen am 06.11.2025
Physical Description:	Online Resource
ISSN:	1533-4406
DOI:	10.1056/NEJMoa2400712